47 completed, 9 terminated, 8 unknown, 5 withdrawn. 23 Phase 2, 15 Phase 3, 8 Phase 1, 7 Not applicable, 7 Phase 4.
Follow Iloprost: new trials by email Literature Review of Iloprost trials Research Report on Iloprost
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease Iloprost, Placebo - Vaso-Occlusive Crises, Sickle Cell Disease | Phase 3 | Not yet recruiting | University Hospital, Rouen | 144 | 2026-09-01 | 2026-03-27 |
| Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension Prostacyclin Pathway Agent, Sildenafil Dose Optimization - Pulmonary Arterial Hypertension (PAH) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 196 | 2026-07-22 | 2026-07-30 |
| Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude Iloprost (Ilomedin, BAYQ6256) - Frostbite, Altitude | Not yet recruiting | Institute of Mountain Emergency Medicine | 10 | 2026-05-01 | 2026-03-09 | |
| Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Biospecimen Collection, Bronchial Brush Biopsy, Bronchoscopy - Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-06-01 | 2024-05-17 | |
| Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure Iloprost, Isotonic saline - Acute Respiratory Failure, Endothelial Dysfunction | Phase 2 | Recruiting | Pär Johansson | 450 | 2024-04-15 | 2025-08-22 |
| A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture 0.125 ng/kg/min Iloprost, 0.25 ng/kg/min Iloprost, open reduction and internal fixation with an angular stable plate (PHILOS) - Proximal Humeral Fracture | Phase 1 / Phase 2 | Unknown | Charite University, Berlin, Germany | 30 | 2022-05-12 | 2022-11-03 |
| Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients 5ml of inhaled normal saline, 20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline - Mediastinal Mass | Not applicable | Unknown | Yonsei University | 60 | 2021-06-24 | 2021-06-15 |
| Effect of Intraoperative Iloprost Inhalant on Hemodynamic Stability in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery Iloprost, Control (Normal saline) - Coronary Artery Occlusive Disease | Not applicable | Unknown | Yonsei University | 100 | 2020-11-04 | 2020-11-05 |
| Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure Iloprost, Isotonic saline - COVID-19, Respiratory Failure | Phase 2 | Completed | Pär Johansson | 80 | 2020-06-15 | 2024-05-07 |
| Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure Iloprost, Isotonic saline - Septic Shock | Phase 2 / Phase 3 | Completed | Jakob Stensballe, MD, PhD | 279 | 2019-10-30 | 2024-05-07 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Completed | Civi Biopharma, Inc. | 198 | 2019-10-14 | 2025-05-25 |
| ILOPROST in Septic Shock With Persistent Microperfusion Defects (I-MICRO) ILOPROST, NaCl - Septic Shock Hyperdynamic | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 240 | 2019-07-03 | 2024-07-03 |
| Iloprost in Acute Respiratory Distress Syndrome Iloprost, control - Respiratory Distress Syndrome, Adult | Phase 3 | Completed | University Hospital Tuebingen | 150 | 2019-06-25 | 2021-12-30 |
| Infusion of Prostacyclin vs Placebo for 72-hours in Trauma Patients With Haemorrhagic Shock Suffering From Organ Failure Iloprost, Isotonic saline - Multi Organ Failure | Phase 2 | Completed | Pär Johansson | 228 | 2019-05-22 | 2024-05-08 |
| Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) Placebo IV infusion, Iloprost Injection, for intravenous use - Raynaud Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Completed | Civi Biopharma, Inc. | 34 | 2019-03-07 | 2025-05-25 |
| Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension Iloprost (Ventavis, BAYQ6256), Breelib nebulizer - Hypertension, Pulmonary | Completed | Bayer | 31 | 2018-02-01 | 2021-05-26 | |
| Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction Iloprost, Placebo - Heart Failure With Normal Ejection Fraction | Phase 4 | Unknown | National Taiwan University Hospital | 34 | 2017-11-29 | 2019-08-14 |
| Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension Iloprost and nitric oxide administration - Pulmonary Hypertension | Phase 4 | Terminated | Duke University | 27 | 2017-07-21 | 2024-04-02 |
| Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension Iloprost - Pulmonary Hypertension, Pulmonary Arterial Hypertension | Not applicable | Completed | University of Giessen | 30 | 2017-05-01 | 2018-10-26 |
| Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH) Ventavis (Iloprost, BAYQ6256) - Hypertension, Pulmonary | Completed | Bayer | 282 | 2016-08-01 | 2024-08-19 |
Showing 20 of 73. Sign in to see all of them.
Hypertension, Pulmonary (25) · Pulmonary Arterial Hypertension (21) · Familial Primary Pulmonary Hypertension (5) · Respiratory Aspiration (5) · Lung Neoplasms (4) · Pulmonary Disease, Chronic Obstructive (4) · Respiratory Distress Syndrome (4) · Scleroderma, Systemic (4) · Raynaud Disease (3) · Heart Defects, Congenital (2) · Patient Compliance (2) · Peripheral Arterial Disease (2) · Persistent Fetal Circulation Syndrome (2) · Shock, Septic (2) · Acute Lung Injury (1)
Bayer (15) · Actelion (10) · Pär Johansson (4) · Yonsei University (3) · Charite University, Berlin, Germany (2) · Civi Biopharma, Inc. (2) · Duke University (2) · National Cancer Institute (NCI) (2) · Shanghai Jiao Tong University School of Medicine (2) · University of Oklahoma (2) · Air Force Military Medical University, China (1) · Assistance Publique - Hôpitaux de Paris (1) · Fadoi Foundation, Italy (1) · Fertility Specialists of Houston (1) · Gachon University Gil Medical Center (1)
United States (24) · Germany (8) · France (7) · Denmark (6) · South Korea (5) · China (4) · Italy (4) · Spain (4) · Portugal (3) · Japan (2) · Poland (2) · Russia (2) · Austria (1) · Belgium (1) · Brazil (1)
Laila Rouault, MD (2) · Wade Benton, Pharm D (2) · York E Miller (2) · Adaani Frost, MD (1) · Anders Perner, MD, PhD (1) · Ben DeBoisblanc, MD (1) · Bernhard Zwissler, Prof.Dr.med. (1) · Caio Fernandes (1) · Charles J. Burch, MD (1) · Chistian Hassager, MD, DMSc (1) · David Baratz, MD (1) · Delphine Yung, MD (1)
PMID 18634152, PMID 19841299, PMID 20153158, PMID 20424447, PMID 20560291, PMID 21636546, PMID 22951358, PMID 23370599, PMID 23400744, PMID 26449137, PMID 27001191, PMID 27484224, PMID 27683610, PMID 28119496, PMID 30756339, PMID 31479003, PMID 31710844, PMID 31849715, PMID 31945586, PMID 31950481, PMID 32131881, PMID 32611377, PMID 32847626, PMID 32966279, PMID 33393084, PMID 34623313, PMID 36805707, PMID 37711198, PMID 38148468, PMID 39259541, PMID 40387381, PMID 40405317, PMID 42110435
2019 (2), P30CA060553 (2), 2004 (1), 2008 (1), 2009 (1), 2017 (1), 2025 (1), N01CN00035 (1), UG1CA242643 (1)